Declaration of interests
AUK reports grant support from the NIH (P50CA09213 and 1R37CA292795) and the Department of Defense (PC210066); contracts from Novartis, Janssen, Lantheus, Varian Medical Systems, and ViewRay Systems; consulting fees from Lantheus, Varian Medical Systems, Novartis, and Janssen; honoraria from Janssen, Boston Scientific, Varian Medical Systems, and Lantheus, and low-value stock in MiraDx and Alethian AI. CCP reports consulting fees from Novartis and Janssen and participation on a data safety montoring board or advisory board for Telix. MRS reports previous emplyoment with the UKRI-MRI; grant suppport from Astellas, Janssen and Sanofi-Aventis; honoraria from Eisai, Eli-Lily, and Janssen; support for travel from the Health Research Board of Ireland, the Trials Methodology Network in Ireland, and the National Cancer Grid in India; and previous participation in several data monitoring committees in an unpaid capacity. LFV reports grants from Bristol Myers Squibb Foundation Winn CDA, National Institutes of Health SPORE Career Enhancement Program, Mike Slive Foundation for Prostate Cancer Research, The Parker Institute for Cancer Immunotherapy, and the US Department of Veteran Affairs; and consulting fees from the Dedham Group and Health Advances. JES reports grants from the National Institutes of Health and Congressionally Directed Medical Research Programs; consulting fees from Boston Scientific and Engaged MD; honoraria from Onclive; and a leadership or fiduciary role in the American Urological Association. JAG reports consulting fees from AstraZeneca, BeiGene USA, Dava Oncology, GlaxoSmithKline, MJH Life Sciences, Pfizer, and Urogen Pharma. JRB reports honoraria from Ipsen and Merck; support for attending meetings or travel for Johnson & Johnson; and participation in data safety monitoring boards or advisory boards for AstraZeneca, Pfizer, and Johnson & Johnson. MBR reports consulting fees from Immune Bio; honoraria from Bayer and Johsnon&Johnson; and a patent for Inhibitors of the N-terminal domain of the androgen receptor. AES reports consulting fees from Adaptyx Biosciences; honoraria from OncLive, ScientiaCME, Targeted Oncology, Eisai; and participation on a data safety monitoring board or advisory board for Aveo Oncology, Bristol Myers Squibb, Eisai, and Exelixis. SE reports consulting fees with Janssen. SR reports grant support from the Prostate Cancer Foundation; honoraria from Specialty Network; and stock with Merck, Pfizer, Eli Lilly, and Johnson & Johnson. NGZ reports grants from the American Cancer Society—Tri State CEOs Against Cancer Clinician Scientist Development Grant, CSDG-20-013-01-CCE (2020–) and the Department of Defense (2020–). AYJ reports grants from Novartis and honoraria from Novartis. JAE reports grants from Blue Earth Diagnostics; consulting fees from Blue Earth Diagnostics, Boston Scientific, and Clarity Pharmaceuticals; honoraria from Elekta, IBA, Genentech, UpToDate, Pfizer, and Astellas; participation on a data safety monitoring board or advisory board for Myovant Sciences, Janssen, Johnson & Johnson, Bayer Healthcare, Progenics Pharmaceuticals, Pfizer, Gilead, Lantheus, Angiodynamics, Bioprotect, MDxHealth, and Boston Scientific; and leadership or fiduciary roles as a board member for the Massachusetts Prostate Cancer Coalition, American College of Radiology, and Radiation Oncology Institute; as well as functioning as the Co-Chair of the NCI GU Steering Committee. OM reports honoraria from Bayer. JJD reports funding from National Cancer Institute and US National Institutes of Health. AP reports a leadership role as the co-chair emeritus of the GU translational research programme at NRG oncology. HMS reports leadership roles as a member of the Board of Directors for ASTRO and Speed of Light, The ASTRO Foundation. PLN reports grants from Bayer, Astellas, and Janssen; consulting fees from Boston Scientific, Augmenix, Janssen, Blue Earth, MDxhealth, AIQ, Novartis, and Bayer; a ledership role in NRG Oncology as the GU Chair; and stock or stock options in Nonocan, Reversal Therapeutics, and Strategen Bio. DES reports grant funding from the National Institutes of Health (U01); consulting fees from Boston Scientific; and honoraria from AstraZeneca, Astellas, Bayer, Blue earth, Janssen, Novartis, and Pfizer. All other authors declare no competing interests.
